Stay updated on REOLYSIN in KRAS Mutant CRC Clinical Trial
Sign up to get notified when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.

Latest updates to the REOLYSIN in KRAS Mutant CRC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page has been updated to include specific drug names and details related to KRAS mutant metastatic colorectal cancer treatment, while significant portions of the previous content describing the study's methodology and eligibility criteria have been removed.SummaryDifference39%
- Check19 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check27 days agoNo Change Detected
- Check63 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check77 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check84 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check99 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to REOLYSIN in KRAS Mutant CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.